Use of novel antipsychotic drugs

Pharmacotherapy

Volumn 16, Issue 6 II, 1996, Pages

  Raleigh, Fred ^a,b,c  

^a Atascadero State Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN ANTAGONIST;

AKATHISIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG EFFICACY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; NEUROTOXICITY; PARKINSONISM; PATIENT CARE; REVIEW; SCHIZOPHRENIA; SEDATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; HUMANS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0029956828     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Janssen Pharmaceutica, Inc. Data on file. Piscataway, NJ; 1996.
2. Marken P, Stanislav A. Schizophrenia. In: Young LY, Koda-Kimble MA. Applied therapeutics: the clinical use of drugs, 6th ed. Vancouver, WA: Applied Therapeutics, 1966:75-8.
3. Casey DE. Motor and mental EPS. Int Clin Psychopharmacol 1995;10(suppl 3):105-14.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-35.
5. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13(1): 25-40.
6. Ames D, Marder SR, Wirshing WC. Risperidone: clinical applications. In: Breier A, ed. The new pharmacotherapy of schizophrenia, 1st ed. Washington, DC: American Psychiatric Association Press, 1996:15-40.
7. Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Ada Psychiatr Scand 1994;89(suppl 380):14-20.
8. Van Putten T. The many faces of akathisia. Contemp Psychiatry 1975;16:43-7.
9. Tardiff K. The current state of psychiatry in the treatment of violent patients. Arch Gen Psychiatry 1992;49:493-9.
10. Van Putten T, May P, Marder S. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 1984;141:16-19.
11. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
12. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;(suppl 212):11-19.
13. Jeffries J. Ethical issues in drug selection for schizophrenia. Can J Psychiatry 1993;38(suppl 3):S70-4.
14. MacEwan G. New antipsychotic medications: do research results relate to clinical practice? Can J Psychiatry 1993; 38:575-9.
15. Levy RH. Sedation in acute and chronic agitation. Pharmacotherapy 1996;16(6 pt 2):152S-9.
16. Cassens G, Inglis A, Applebaum P, Gutheil T. Neuroleptics: effects of neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16:477-99.
17. Meltzer H, Lee M, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand 1994;(suppl 384):95-101.
18. Gallhofer B. Effects of conventional and atypical agents on cognitive function in schizophrenia. Presented at the annual meeting of the American Psychiatric Association, New York, NY, May 4-9, 1996.
19. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996;57(suppl 3):39-45.
20. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34(10):702-12.